We recently modeled Transient Receptor Potential Channels (TRP) channels using the Gestalt Domain Detection Algorithm-Basic Local Alignment Tool (GDDA-BLAST) which derives structural, functional, and evolutionary information from primary amino acid sequence using phylogenetic profiles(1). Herein we test our functional predictions for the TRP_2 domain of TRPC3; a domain of unknown function that is conserved in all TRPC channels. Our functional models of this domain identify both lipid-binding and trafficking activities. In this study, we reveal: (i) a novel structural determinant of ion channel sensitivity to lipids, (ii) a molecular mechanism for the difference between diacylglycerol(DAG) -sensitive and DAGinsensitive TRPC subfamilies, and (iii) evidence that TRPC3 can comprise part of the vesicle fusion machinery. Indeed, the TRPC3 TRP_2 domain mediates channel trafficking to the plasma membrane and binds to plasma membrane lipids. Further, mutations in TRP_2 which alter lipid-binding also disrupt the DAG-mediated fusion of TRPC3-containing vesicles with the plasma membrane in response to without disrupting SNARE interactions. Importantly, these data accord with the known role of DAG in membrane destabilization which facilitates SNAREdependent synaptic vesicle fusion(2;3). Taken together, functional models generated by GDDA-BLAST provide a computational platform for deriving domain functionality which can have in vivo and mechanistic relevance.
Introduction
TRP channels are a superfamily of diverse ion channels that are central to the regulation of physiological processes such as sensory perception (4), cell development and growth(5;6), hearing (7;8) , taste (9) , and fertility(10) as well as multiple diseases including mucolipodosis (11;12) and polycystic kidney disease (11;13;14) . TRP channels comprise a cellular Ca 2+ entry pathway that responds to stimulation with Ca 2+ mobilizing agonists (15) . Their channel activation can be influenced by phosphorylation, nitrosylation, glycosylation, protein-protein interactions, protein-lipid interactions, mechanosensation, temperature, Ca 2+ store-depletion, and exocytosis (14;16) . This polymodal activation scheme is complex and underscores the reason why it is difficult to study the role of TRP channels within biological processes. This is compounded by the fact that: (i) TRP channels can form multimers with other TRP isoforms, and (ii) there is, in general, a lack of domain annotation for TRP channels. Therefore, reconciling the results obtained with an exogenously expressed channel to those observed with endogenous channels is challenging as is predicting protein regions underlying specific functionalities.
The canonical TRP (TRPC) channels are so named because they are closest to the prototypical Drosophila TRP channel which mediates photoreception in the fly eye (17) . Importantly, TRPC channels have been directly linked to brain development (14;18) , smooth muscle contraction (14;19) , neuronal guidance and outgrowth (6;20;21) , as well as cardiovascular disease and glomerulosclerosis (22;23) . Through a yet unknown mechanism, TRPC channels are activated in response to the receptor second messengers inositol-1,4,5-trisphosphate (IP 3 ) and DAG (reviewed in (14;16) ). Importantly, TRPC channels can be subdivided into two subfamilies: the DAG-sensitive TRPC channels (C3/6/7) and the DAG-insensitive TRPC channels (C1/4/5).
Multiple binding and regulatory activities have been empirically identified for TRPC channels. For example, two lipid-binding sites have been identified in the DAGsensitive TRPCs (24;25) . Specifically, the extreme Nterminal lipid-binding domain binds to phosphatidylinositol-4,5-bisphosphate (PIP 2 ) and regulates TRPC3 plasma membrane surface expression. Similarly in TRPC6, a the C-terminal lipid-binding domain exists that binds to phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ), mediating calmodulin binding (24) . This domain is conserved in all DAG-sensitive TRPCs, suggesting that they too share this functional domain. Conversely, formal queries of TRPC protein sequences using popular domain detection algorithms (e.g. Pfam, SMART, NCBI-CDD, InterProScan), yield no information about the nature or location of lipid-binding domains. In general, these programs predict that TRPC channels contain only one functional domain (ion channel), and two domains whose function is unknown (ankyrin, TRP_2), thus leaving the majority of the protein without functional annotation.
We present here a comparative and physiological analysis of the TRP_2 domain within TRPC3. Our in silico (1) , in vitro, and cellular assays reveal that the TRP_2 domain in TRPC channels is a lipidbinding/trafficking domain which, when mutated, alters the fusion of DAG-sensitive TRPC3-containing vesicles with the plasma membrane. Further, these results suggest that like TRPM7 (26) , TRPC channels also have a "SNARE-like" activity and be directly involved in vesicle fusion.
Materials and Methods
Lipid-binding Assays-PIP strips: as per manufacturer's instructions using 500-1000 ng of purified protein (25) . Lipid-binding Liposomes: performed as previously described (27) . Briefly, lipid mixtures phosphatidylethanolamine (29.2%), phosphatidylcholine (29.2%), phosphatidylserine (29.2%), and phosphatidyl-inositol (12.5%) (all in CHCl 3 ) were dried down to form a thin film in a 0.5-ml minifuge tube (Beckmann) and then bath sonicated in 0.2 M sucrose, 20 mM KCl, 20 mM Hepes, pH 7.4, 0.01% azide to yield a 10× dense lipid stock. This was diluted 1:10 in dilution buffer (0.12 M NaCl, 1 mM EGTA, 0.2 mM CaCl 2 (free Ca 2+ concentration of approximately 50 nM), 1.5 mM MgCl 2 , 1 mM dithiothreitol, 5 mM KCl, 20 mM Hepes, pH 7.4, 1 mg/ml bovine serum albumin) containing 500-1000 ng of recombinant protein. Protein complexes were allowed to form by incubation at 30 °C for 5 min prior to centrifugation (100,000 × g for 30 min). After spinning, supernatants were carefully removed and the pellets retrieved by addition of an equal volume of 60 °C SDS sample buffer and subsequent bath sonication. Both PIPstrip and liposomal assays were visualized via Western analysis. Films were scanned and analyzed using Bio-rad Gel-dock© system (p-values from student t-test). Cell culture and Transfection-HeLa cells and HEK293 cells were from American Tissue Culture Collection (Manassas, VA, USA). Cells were grown in DMEM supplemented with 10% FBS and 1% Streptomycin (all from Atlanta Biologicals, Altanta, GA). HEK cells were transfected by electroporation, or, like HeLa cells, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). PC12 cells were cultured as previously described (28) . Ca 2+ imaging-For standard fluorescence recording experiments, cells grown on coverslips were loaded with 2 µM Fura-2AM in the standard solution, that contained (in mM) 150 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, pH adjusted to 7.2 with 10 mM HEPES. Following 30 min at incubation 37ºC and a wash, the coverslips were placed in the perfusion chamber that allows rapid exchange of bath solutions. The solutions were applied by bath perfusion with ten volumes of the perfusion chamber. Fura-2 was excited by alternating 340/380 nm light and the resulting 510 nm fluorescence was recorded through a CCD-cooled camera and analyzed using Metafluor software (Molecular Devices, Sunnyvale, CA). All data in Supplemental Fig  1a- b are averages of ~30 cells from 3 independent experiments. The quantification of the calcium imaging in Fig 2b reflects the area under the curves for OAG and carbachol, respectively (% of WT, p-values from student ttest). Electrophysiology-For conventional whole cell recording, cells grown on coverslips were placed in a perfusion chamber that was secured on the stage of an inverted microscope equipped with a fluorescent illuminator and filters designed to identify GFP-expressing cells. Transmembrane currents were recorded using an HEKA EPC-10 amplifier (HEKA Instruments, Southboro, MA), stored in a PC and analyzed using Patchmaster and Origin software. Currents were digitized at 1 kHz and filtered through low-bandpass filter set at 5 kHz cutoff frequency. In whole-cell mode, the pipette solution contained (in mM) 140 Cs-Aspartate (to cancel endogenous K+ and Cl-conductances), 5 NaCl, 5 Mg-ATP, 10 HEPES, 2 EGTA or 10 BAPTA, pH 7.2. The standard bath solution contained (in mM): 140 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, pH 7.5. In some experiments, NaCl was replaced with NMDG-Glutamate and 0 or 10 mM divalent metals were included in the bath solutions. The experiments were performed at room temp.
The solutions were applied by bath perfusion with ten volumes of the perfusion chamber. Pipette resistance was in 2 to 4 MOhm range and seal resistance was always over 1 GOhm. Series resistance and capacitance were compensated using the proprietary protocol included with Patchmaster.
Confocal
Immunofluorescence AnalysesFor experiments with fixed cells, cells grown on glass coverslips were fixed and permeabilized by 10 min incubation at -20ºC with 100% methanol, or were fixed by a 5 min incubation with 3.7% formaldehyde and permeabilized by incubation with 0.01% Triton X-100 at 4ºC for 5 min. After fixation, non-specific sites were blocked by incubation in 5% goat serum. Subsequently the cells were incubated with the primary antibodies in blocking solution. Following wash-out of the primary antibodies with PBS, the cells were stained with fluorescent secondary antibodies and analyzed as above. The slides were placed on the stage of a BioRad 1024 confocal microscope and fluorescence was recorded and analyzed offline using ImageJ software. Dextran Loading: Fibroblasts transfected with TRPC3 constructs were loaded with 5 mg/ml 10 KDa texas Red tagged Dextran (Molecular Probes, Carlsbad, CA). Following a 3 h load, cells were fixed and processed for confocal immuno-cytochemistry as discussed above. EM-HeLa cells were fixed by 30 min incubation with a solution containing 2.5% Glutaraldehyde in 0.1M NaCacodilate, washed with 0.1M Na-Cacodilate, and freezethaw permeabilization of the membranes, cells were incubated overnight with α-myc antibodies, rinsed and biotinylated secondary antibodies were added. After an extensive wash, the samples were incubated with avidinperoxidase and washed. Next, 3,3'-diamino-benzidine was added for 10 min and, after another wash, the samples were post-fixed with a solution containing 1% OsO4, washed with PBS and stained en block for 30 min with 2% Uranyl Acetate. Following dehydration by immersion in 30% to 100% ethanol, the samples were embedded in resin by immersion in 30% to 100% resin:propylene oxide mixtures. Fixed samples were mounted on grids and analyzed with a JEOL 100CX transmission electron microscope. Stable cell lines-C-terminally tagged YFP-TRPC3 was engineered and cloned into peYFP vector from Clontech (Mountain View, CA). These vectors were transfected into HEK-293 cells, using lipofectamine2000© as per manufacturers instructions. 24 hours post-transfection, cells were passed at low density into 96 well plates and grown in 500 μg/ml G418. Wells that formed colonies were sub-cultured and assayed for stability by YFP-TRPC3 expression. These cells were expanded and frozen in liquid nitrogen. Stable cell lines were only used for 10 passages to ensure reproducibility. FLIP/FRAP-Stably transfected WT or SS YFP-TRPC3 cells were plated onto poly-D-lysine coated coverslips 24 h before use. Cells were treated with 10 μg/ml cyclohexamide for 1 h before use to block new protein synthesis. All experiments were performed on the Olympus FV1000 laser scanning confocal microscope (Olympus America Inc., Melville, NY). This was performed with an inverted Olympus IX-81 microscope using a blue argon laser and a 60X oil immersion (1.42 NA) PlanApo lens. FV10-ASW software was used for the analysis. All experiments were performed at room temperature. FRAP-cells were bleached at 100% laser power for 5 seconds over a series of 3 different (oval, rectangle, square) standardized ROI sizes. Recovery from bleaching was then measured for 90 seconds at 3 second intervals.
FLIP-Cells were bleached at 100% laser power for 10 seconds and then given 20 seconds for recovery (12 total bleaches). Three standardized (total pixel volume) ROI's (oval, rectangle, square) were measured at the beginning of each bleach. Each ROI was further measured using the following method. Three standardized circles were placed either in the area under the membrane or on the plasma membrane. These circles were then quantified and averaged and p-values determined by student t-test. This allowed us to separate cytosolic TRPC3 movement from TRPC3 movement at the plasma membrane. TIRF-TIRF measurements were obtained using an enclosed Nikon 2000U epi-microscope maintained at 37 0 C. The microscope is outfitted with a TIRF module, a Nikon 60X Apo 1.6N/A oil-immersion lens, Prior stage, and Roper512 CCD camera. Excitation was performed at 488nm. Cells were incubated in Krebs buffer and allowed to equilibrate 5 min before measurements. Z-position was standardized using the Prior stage controls. Cells were imaged without stimulation for 180 cycles, followed by 180 cycles of measurement in the presence of 100 μM carbachol. Analysis was performed using MetaFluor software©. Protein Purification-TRPC3 fragments were cloned into Pet28c HIS-tagged vectors and transformed into BL21 bacteria. Protein production was induced by 100 μM IPTG for 30 minutes at 37 0 C. Cells were lysed by sonication in lysis buffer (PBS containing 100 mM EDTA, 1 mM PMSF, 5 mM DTT, and complete protease inhibitor mixture). After lysis, debris is pelleted by a 5 minute 10,000 x g centrifugation. The supernatant was incubated on Talon© beads for 30 minutes, washed 10 times with TBST, and eluted with 500 μl of 10 mM EDTA in TBS pH 8. Proteins were then dialyzed 2X with 4L of TBS pH 7.4 to remove detergent and EDTA. Cell surface biotinylation-Performed as previously described (25) . Antibodies and Reagents-HIS Pet28c vectors from Novagen (San Diego, CA). Lipids for liposomal assays were from Avanti (Alabaster, AL). PIP-strips were from Echelon (Salt Lake City, UT). Talon beads from Clontech (Mountain View, CA). Streptavidin beads, Fura 2AM, and Lipofectamine2000© from Invitrogen (Carlsbad, CA). All other reagents were from Sigma (St. Louis, MO). DIIKA: The dominant-negative dynamin 2 K44A mutant (D2KA) unable to hydrolize GTP was a gift of Dr. Joseph P. Albanesi (Dept Pharmacology, UT Southwestern). Antibodies were used as to the manufacturer's instructions.
Results

Peripheral lipid-binding and activity
TRPC3 has two known lipid-binding domains that are not predicted by conventional domain detection algorithms (24;25) . Using GDDA-BLAST, we observe multiple putative lipid-binding regions in TRPC channels, including predictions for both regions of TRPC3 that have been experimentally validated to bind lipid(1). We also predict lipid-binding activity in the domain of unknown function, TRP_2. We observe that most of the conserved residues from GDDA-BLAST analysis occur between G197 and D233 in TRPC3(1). We performed multiple sequence alignments between all of the human TRPC channels in this region and observe that DAG-sensitive TRPC3/6/7 have a non-synonymous substitution (S209) when compared to DAG-insensitive TRPC1/4/5 (Fig 1a) . Additionally, S213 in TRPC3 is a phenylalanine in TRPC1.
Based on these data, we mutated TRPC3 to mirror TRPC1 (S209R/S213F, herein referred to as SS mutant). We tested the prediction that TRP_2 binds peripheral lipids in the physiologically relevant liposomal assay constructed to mimic plasma membrane lipid composition. We observe that SS TRPC3 has significantly increased lipid-binding versus WT or a K202A/R204A (KR) mutant (Fig 1b) . We were unable to test whether DAG is capable of binding to this peptide as DAG disrupts liposomal formation; however, we did not observe WT or SS binding to PIP-strips© containing immobilized DAG (data not shown).
Next, we tested whether the SS mutation alters channel activity of overexpressed TRPC3 in response to the G-protein receptor agonist carbachol (which increases endogenous IP 3 and DAG) or the cell permeant DAG analogue 1-oleoyl-2-acetylglycerol (OAG). In HEK293 cells transiently transfected with either myc-tagged WT or SS TRPC3, the SS mutation reduces overall channel activity in response to either carbachol or OAG as measured by Fura-2 AM and whole-cell electrophysiological recordings (Fig 2a-c, Supplemental  Fig 1a-b) . In data not shown, we observe small but reproducible SS activity in a subpopulation of cells.
Localization
The above observations suggest that the SS mutation alters either channel activity and/or levels of TRPC3 in the plasma membrane (i.e. trafficking). This accords with predictions derived by GDDA-BLAST for trafficking activity with the TRP_2 domain of TRPC3(1). Therefore, we conducted a series of experiments to determine if the SS mutation alters TRPC3 trafficking. We performed confocal microscopy on HeLa cells transfected with full length WT or SS TRPC3 (Fig 3a, Supplemental  Fig 1c) . We observe no overt differences in localization of SS compared to WT expression. Further, co-expressed WT and SS TRPC3 colocalize within the same cellular regions (Fig 3a) . To address whether vesicle trafficking near the plasma membrane was altered, we performed Total Internal Reflection Fluorescence microscopy (TIRF) on WT or SS TRPC3 stably expressed in HEK293 cells (Fig  3b, Supplemental Fig 1d and Supplemental Movies), which assays vesicle movement within ~100 nm of the plasma membrane. We found that SS positive vesicles are indistinguishable from WT in both size and movement. We next performed transmission electron microscopy on HeLa cells overexpressing myc-tagged TRPC3 stained with anti-myc antibodies (Fig 4a) . We do not observe any gross changes between WT and SS localization, although irregular blebbing can be observed near the plasma membrane in the SS preparations. These results show either there is no abnormality in SS mutant localization or that such abnormalities manifest at a stage immediately preceding the mutants' interaction with the plasma membrane.
Trafficking
As obtaining precise measurements of vesicle mobility using TIRF is challenging, we sought a more quantifiable method. Thus we utilized Fluorescence Recovery After Photobleaching (FRAP), and Fluorescence Loss In Photobleaching (FLIP) experiments to more accurately quantify the mobility of vesicles containing WT and mutant channels (Fig 4b-c, Supplemental Fig 1e) . We used FRAP to test forward trafficking and FLIP to assay endocytosis and plasma membrane mobility (see Methods). In the FRAP experiments, we observe recovery of WT TRPC3 fluorescence, an effect which is significantly decreased in SS preparations (Fig 4b) . This result suggests that the sites occupied by SS TRPC3 are not subject to normal recycling. Thus, the plasma membrane cannot be repopulated with unbleached SS TRPC3. Our FLIP experiments demonstrate that WT TRPC3 is depleted from the unbleached area in a time dependent manner (Fig 4c) . This represents vesicle endocytosis and diffusion of WT in the plasma membrane. Conversely, SS TRPC3 is rapidly depleted from areas subjacent to the plasma membrane as WT (Fig 4c,  Cytosolic ROI ), yet has significantly increased retention time with the plasma membrane (Fig 4c, Membrane ROI) . With respect to the Membrane ROI, we observe a biphasic response whereby WT and SS are indistinguishable at early time points but differ significantly at later time points. The lack of effect in early time points could be due to multimerization of SS TRPC3 with endogenous TRPC channels or TRPC channels within the ROI which have yet to dock. Nevertheless, the reduced mobility of SS at the plasma membrane is consistent with our finding that this mutant has increased affinity for plasma membrane lipids (see Fig 1b) .
The decreased activity of the SS mutant could be due to altered vesicle insertion, endocytosis, and/or channel gating. To more rigorously evaluate whether endocytosis of the SS mutant is disrupted, we performed fluorescent dextran loading assays (Fig 5a) . WT TRPC3 (green) co-localizes with internalized dextran, while only a fraction of dextran containing vesicles are positive for SS TRPC3, in accord with the results from our FLIP/FRAP experiments, indicating that endocytosis of the SS mutant is impaired. Next, we tested mutant channel activity in the presence of a dominant-negative form of dynamin (DIIKA), which blocks endocytosis (29) (Fig 5b-c) . Under these conditions we observe increased SS TRPC3 channel cell surface expression, as well as activity via Fura-2AM using Ba 2+ as the charge carrier. Combined with the dextran loading assays, these data suggest that the SS defect(s) are not caused by decreased half-life in the plasma membrane or alterations in channel gating.
Although immunostaining, TIRF, and electron microscopy cannot distinguish between WT and SS channel localization at the plasma-membrane (Fig 3 and  4a) , these data would not reveal alterations in SNARE activity. Indeed, amino acids 123-221 of TRPC3 have been shown to bind to VAMP-2 directly, while another uncharacterized region in the N-terminus binds directly to the SNARE protein αSNAP (soluble N-ethylmaleimidesensitive factor attachment protein) (30) . These authors reported that the exocytotic insertion of TRPC3 channels is mediated by a VAMP-dependent, and calciumindependent process. Our in vitro lipid-binding studies were performed with WT and SS TRPC3 preparations of amino acids 161-280 (see Figure 1b) , which includes a portion of the VAMP interaction site. Thus, to rule out possible effects directly on membrane fusion machinery, rather than lipid-binding, we performed dominant negative experiments using cloned fragments of TRPC3 (121-280 WT or SS, and 161-280 WT or SS), which were transfected HEK293 cells (Fig 6a-b) .
Our experimental predictions are as follows: (i) if the SS mutation interferes with VAMP-2/αSNAP binding, only the 121-280 WT fragment should act as a dominant negative for WT TRPC3 activity/surface expression; (ii) if, however, the 121-280 SS fragment doesn't interfere with SNARE binding, both WT and SS peptides should function as a dominant negatives; (iii) if the lipid-binding TRP_2 region in TRPC3 (aa 161-280) binds to VAMP-2/αSNAP, the 161-280 WT fragment should act as a dominant negative; (iv) if, however, the 161-280 WT and SS peptides do not act as dominant negatives than this implies that the defects associated with the SS mutation are independent of SNARE interactions.
Indeed, Fura2AM measurements within intact HEK293 cells transfected as above reveal that 121-280 WT and SS act as dominant negatives and are equally effective at inhibiting TRPC3 activity whereas 161-280 preparations do not (Fig  6a) . Furthermore, this data suggests that the VAMP-2 binding site can be more narrowly defined between amino acids 121-161. We extended these finding by assaying the surface expression of TRPC3 under the aforementioned preparations. Cell surface biotinylation experiments demonstrate that co-expression of either 121-280 WT or SS fragments inhibits the OAG-mediated surface expression of TRPC3, whereas the 161-280 WT fragment is as control (Fig 6c) .
Fusion
These above results suggest that the SS mutation alters either the docking and/or fusion of channelcontaining vesicles. To address this supposition, we assayed levels of overexpressed TRPC3 in the plasma membrane using cell-surface biotinylation. Cells stimulated by tyrosine kinase receptor (epidermal growth factor (EGF)), OAG (Fig 7a-b) , or G-protein coupled receptor (carbachol-data not shown) manifest increased levels of WT TRPC3 in the plasma membrane, an effect that is inhibited by the SS mutation. Moreover, in nontransfected PC12 cells which express endogenous TRPC3, treatment with OAG, RHC (a DAG-kinase inhibitor which increases endogenous levels of DAG), or carbachol elicits a substantial increase in endogenous TRPC3 surface expression within 1 min, while endogenous DAGinsensitive TRPC5 levels are unaltered (Fig 8a) .
OAG promotes TRPC3 activity, but the mechanism of this action has not been elucidated(2;3;31) perhaps due to inconsistencies between the endogenous and overexpressed channels (32;33) . This is further illustrated by our Ca 2+ entry measurements in nontransfected PC12 cells (Fig 8b) . We do not observe significant Ca 2+ activity following OAG or RHC stimulation despite the fact that TRPC3 cell surface levels increase with these treatments (Fig 8a) . The lack of channel activity in response to OAG and RHC treatment is likely due to phosphorylation of endogenous TRPC3 by protein kinase G or C, both of which have been shown to have an inhibitory action on OAG-mediated calcium flux (34;35) . These results suggest that DAG does not "activate" TRPC channels per se, rather it increases the fusion of TRPC3-containing vesicles with the plasma membrane (Fig 5d) (15) . DAG-induced fusion is well supported by the literature(2;3) as this molecule is a known membrane destabilizer which promotes the fusion of neurotransmitter-containing vesicles both physiologically (e.g. via receptors) and pathophysiologically (e.g. via snake presynaptic phospholipase A2 neurotoxins) (36) . In whole, our results demonstrate that the TRP_2 domain in TRPC3 is a lipid-binding domain that participates in membrane fusion.
Discussion
In summary, GDDA-BLAST yielded accurate predictions of a new functional domain in TRPC channels(1). Our experimental evidence demonstrates that TRPC3 TRP_2 is a lipid/trafficking domain that contributes to DAG-sensitive vesicle fusion. The TRPC3 SS mutation within the TRP_2 domain has: (i) increased affinity for plasma membrane lipids, (ii) decreased mobility when associated with the plasma membrane, and (iii) deficits in DAG-induced plasma membrane insertion, upstream of SNARE interactions. We propose that the increased affinity for plasma membrane lipids inhibits the membrane destabilization of TRPC3-containing vesicles by DAG. In support, DAG is a well characterized coneshaped lipid that destabilizes membranes at synapses, thus increasing vesicle fusion(2;3). DAG increases the negative curvature of membranes (i.e. propensity to form nonbilayer phases while keeping lamellar architecture), increases spacing between phospholipid headgroups (i.e. alters fluidity), and decreases membrane surface hydration which may help the docking of proteins to membranes or micellar substrates.
While the N-terminus of TRPC3 (121-280) can functions as a dominant-negative of SNARE activity and vesicle fusion, this is independent of the lipidbinding/trafficking activity of the TRP_2 domain (Fig 7) . Indeed, we and others have previously suggested a secretion-like coupling model for Ca 2+ entry mechanisms (30;37;38). For example, Ambudkar and colleagues previously demonstrated that an N-terminal region of TRPC3, inclusive to the TRP_2 domain, can associate with synaptobrevin/VAMP and α-SNAP while co-localizing with many of the known SNARE machinery components (30) . Importantly, VAMP and TRPC3 must exist in the same vesicles for fusion. Hence, TRPC3 likely comprises part of the SNARE machinery within vesicles it occupies, as has been proposed for TRPM7 (26) . This idea is supported by our identification of SNARE domain "fingerprints" in TRPC3 channels with GDDA-BLAST(1). Furthermore, these data imply that cargo contained in SS TRPC3 vesicles also have defects in plasma membrane insertion.
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